Denmark· DK-28106195718
Isturisa
A osilodrostat product containing osilodrostatphosphat, registered in Denmark by Recordati Rare Diseases. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Osilodrostat is registered in 14 of 19 countries.
Countries holding a registration under ATC H02CA02 (osilodrostat), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Osilodrostat · ATC H02CA02
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of osilodrostat costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.21 in France to $389.38 in Italy — a ×1832 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Osilodrostat · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- IT Italy$389.38
- CH Switzerland$250.17
- FR France$0.21
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Osilodrostatphosphat
- Manufacturer
- Recordati Rare Diseases
- Country
- Denmark (DK)
- ATC code
- H02CA02
- ATC class
- Osilodrostat
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106195718
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
488 interactions on record for osilodrostat.
Graded by severity as the source publishes them — 117 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Osilodrostat · interactions on record
488 records
- 117 severe
- 361 moderate
- 10 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H02CA02
Osilodrostat, as other registers publish it.
- United StatesIsturisaRecordati Rare Diseases, Inc.
- PolandIsturisaRecordati Rare Diseases
- FinlandIsturisaRecordati Rare Diseases
- FinlandIsturisaRecordati Rare Diseases
- United StatesIsturisaRecordati Rare Diseases, Inc.
- PolandIsturisaRecordati Rare Diseases
- FinlandIsturisaRecordati Rare Diseases
- DenmarkIsturisaRecordati Rare Diseases
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ecf1d034-657a-4f6a-85ed-a4ef27388244 GET /v1/drugs/ecf1d034-657a-4f6a-85ed-a4ef27388244?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "5 mg",
"auth_role": "MOD",
"dk_drugid": "28106195718",
"substance": "Osilodrostatphosphat",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43839"
}See everything about osilodrostat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.